Target family: Chromatin modifying enzymes (<i>Plasmodium</i> spp.) (type: other_protein)
Target: Plasmodium falciparum histone deacetylase 1

Ligand: panobinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: EMA & FDA (2015)
Primary target: no
Median affinity: 6.929999828338623 pIC50
Reference (Journal): Chemical signatures and new drug targets for gametocytocidal drug development.
Published in: Sci Rep

Ligand: panobinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: EMA & FDA (2015)
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
Published in: Int J Parasitol Drugs Drug Resist

Ligand: panobinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: EMA & FDA (2015)
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
Published in: Int J Parasitol Drugs Drug Resist

Ligand: panobinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: EMA & FDA (2015)
Primary target: no
Median affinity: 6.03000020980835 pIC50
Reference (Journal): Chemical signatures and new drug targets for gametocytocidal drug development.
Published in: Sci Rep

Ligand: panobinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: EMA & FDA (2015)
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.
Published in: Int J Parasitol Drugs Drug Resist

Ligand: JX35 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.909999847412109 pIC50
Reference (Journal): Drug Repurposing of Quisinostat to Discover Novel <i>Plasmodium falciparum</i> HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety.
Published in: J Med Chem

Ligand: JX35 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Drug Repurposing of Quisinostat to Discover Novel <i>Plasmodium falciparum</i> HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety.
Published in: J Med Chem

Ligand: JX35 (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.899999618530273 pIC50
Reference (Journal): Drug Repurposing of Quisinostat to Discover Novel <i>Plasmodium falciparum</i> HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety.
Published in: J Med Chem

Ligand: quisinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.279999732971191 pEC50
Reference (Journal): A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1.
Published in: Cell Discov

Ligand: quisinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pEC50
Reference (Journal): A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1.
Published in: Cell Discov

Ligand: panobinostat (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: EMA & FDA (2015)
Primary target: no
Median affinity: 6.829999923706055 pIC50
Reference (Journal): Chemical signatures and new drug targets for gametocytocidal drug development.
Published in: Sci Rep